Piramal Pharma Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

The Piramal Pharma stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Piramal Pharma share price prediction as one data point and not as a guarantee of future performance.

This article reviews every dimension of the Piramal Pharma stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

What Analysts Predict for Piramal Pharma Stock in 2026

Analyst consensus on the Piramal Pharma stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and ICICI Securities. All figures are sourced from publicly available research and should be verified before publishing.

Brokerage	Rating	Piramal Pharma Stock Prediction (Rs)	Updated
JM Financial	Neutral	Rs 195	2026
ICICI Securities	Neutral	Rs 175	2026
Analyst Consensus	—	Rs 185	2026

The Piramal Pharma stock prediction range reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Piramal Pharma stock forecast from the current price of Rs 163.51 may or may not be realised by end of 2026.

Piramal Pharma Company Overview

Piramal Pharma is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Piramal Pharma stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.

Metric	Value
NSE Ticker	PPLPHARMA
Sector	Pharmaceuticals and Healthcare
CMP	Rs 163.51 (2026)
52 Week High	Rs 221
52 Week Low	Rs 132
Market Cap	Rs 21,787 Cr
P/E Ratio	28.2
Piramal Pharma Stock Prediction Consensus (12M)	Rs 185

Piramal Pharma Stock Prediction by Time Horizon

Analysts split the Piramal Pharma share price prediction across time frames as near-term drivers differ materially from the long-term view.

Short-Term Piramal Pharma Stock Prediction

The near-term Piramal Pharma stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 163.51 are being watched closely. A short-term Piramal Pharma share price prediction carries the most uncertainty of any time horizon.

12-Month Piramal Pharma Stock Prediction

JM Financial targets Rs 195 (Neutral) and ICICI Securities targets Rs 175 (Neutral). Most desks refresh their Piramal Pharma stock forecast within two to four weeks of each quarterly earnings print. The Piramal Pharma share price prediction should be verified against the most recent analyst reports.

Long-Term Piramal Pharma Stock Prediction

The long-term Piramal Pharma stock prediction is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. The long-term Piramal Pharma share price prediction carries the most uncertainty and should be treated as directional guidance only.

Piramal Pharma Stock Forecast: Key Factors

The following four factors appear consistently in research reports on the Piramal Pharma stock prediction and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Piramal Pharma stock forecast. USFDA approval timelines and price erosion rates directly affect the Piramal Pharma share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Piramal Pharma stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Piramal Pharma share price prediction. New product approvals are cited as catalysts for the Piramal Pharma stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Piramal Pharma stock forecast. Margin recovery strengthens the Piramal Pharma share price prediction from most research desks.

Piramal Pharma Stock Prediction: Bull and Bear Scenarios

Scenario	Piramal Pharma Stock Prediction	Key Conditions
Bull Case	Rs 195	Strong execution, margin improvement, favourable macro and sector re-rating
Base Case	Rs 185	Steady performance, gradual recovery, margins hold, growth on track
Bear Case	Rs 132	Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Piramal Pharma stock forecast of Rs 195 assumes most positive variables converge. The base case of Rs 185 is the analyst consensus and may or may not be achieved.

How Analysts Are Reading the Piramal Pharma Stock Story

Analyst reviews of the Piramal Pharma share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the Piramal Pharma stock prediction consensus is built on real business strengths set against real risks.

Key Risks to the Piramal Pharma Stock Prediction

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Piramal Pharma stock prediction. A facility closure would force an immediate sharp revision to the Piramal Pharma share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Piramal Pharma stock forecast. Aggressive price erosion pushes the Piramal Pharma share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Piramal Pharma stock prediction. The Piramal Pharma share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Piramal Pharma stock forecast. Currency risk is embedded in conservative Piramal Pharma share price prediction models.

How to Monitor the Piramal Pharma Stock Forecast

Track the Piramal Pharma share price prediction consensus quarterly. After every earnings release, most brokerages revise their Piramal Pharma stock forecast within two weeks. Comparing the revised Piramal Pharma stock prediction to the previous estimate tells you whether analyst sentiment is improving or deteriorating.

Compare the current price of Rs 163.51 with the analyst target range of Rs 195 to Rs 175. A wide Piramal Pharma stock prediction band reflects genuine uncertainty, so position size should reflect that range rather than the midpoint alone.

Review the Piramal Pharma share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.

Check Live Piramal Pharma Fundamentals on the Univest Screener

Conclusion

The Piramal Pharma stock prediction for 2026 reflects the analyst community’s assessment of Piramal Pharma’s competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 195 while ICICI Securities has a Neutral rating with a target of Rs 175, giving an analyst consensus of Rs 185.

The Piramal Pharma stock forecast is set against near-term risks that make the Piramal Pharma share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking changes in the Piramal Pharma stock prediction over time is more valuable than relying on any single estimate.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Download the Univest iOS App or Univest Android App to track the live Piramal Pharma stock prediction and share price prediction changes in real time.

Frequently Asked Questions on Piramal Pharma Stock Prediction 2026

What is the Piramal Pharma stock prediction for 2026?

Ans. The Piramal Pharma stock prediction for 2026 is based on analyst consensus from JM Financial and ICICI Securities. The consensus target is Rs 185. All estimates may or may not be achieved.

Is the Piramal Pharma stock prediction bullish or bearish?

Ans. JM Financial has a Neutral rating with target Rs 195. ICICI Securities has a Neutral rating with target Rs 175. The Piramal Pharma stock forecast reflects genuine analyst diversity of opinion.

What is the Piramal Pharma share price prediction based on fundamentals?

Ans. The Piramal Pharma share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Piramal Pharma closely cite these as the primary drivers of the 2026 outlook.

What is the long-term Piramal Pharma stock prediction?

Ans. The long-term Piramal Pharma stock prediction assumes the company sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 185 is the nearest reliable anchor point.

What are the key risks to the Piramal Pharma stock prediction?

Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every Piramal Pharma stock prediction should be read alongside its risk assumptions.

What does the Piramal Pharma stock forecast say for 2026?

Ans. JM Financial: Neutral target Rs 195. ICICI Securities: Neutral target Rs 175. These Piramal Pharma share price prediction estimates may or may not prove accurate.

Where can I track the latest Piramal Pharma stock prediction?

Ans. Track the latest Piramal Pharma stock prediction on the NSE and BSE websites and on the Univest app and screener for live price and updated analyst targets.